Trials
3 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency (2 trials)
- Main trialPhase 3
- “The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.”In the company’s words, NCT04706013 on ClinicalTrials.gov
- Other names
- Pyridoxal Phosphate
Coming up2
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 15 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07928388
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Sep 2027 | Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency | |
| Phase 3Recruiting | 15 Jul 2029 | Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency | |
| Phase 3Authorised | not given | Study of Oral MC-1 for the Treatment of Patients with PNPO Deficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026